Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.630
+0.110 (7.24%)
At close: Nov 20, 2024, 4:00 PM
1.620
-0.010 (-0.61%)
Pre-market: Nov 21, 2024, 4:59 AM EST
Iterum Therapeutics Employees
Iterum Therapeutics had 14 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,182,429
Market Cap
37.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
FibroGen | 486 |
HOOKIPA Pharma | 179 |
Co-Diagnostics | 155 |
DURECT | 58 |
AN2 Therapeutics | 41 |
Elevation Oncology | 29 |
Eterna Therapeutics | 8 |
OKYO Pharma | 3 |
ITRM News
- 6 days ago - Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Iterum Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 23 days ago - Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript) - Seeking Alpha
- 24 days ago - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - PRNewsWire
- 26 days ago - Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - GlobeNewsWire
- 26 days ago - US FDA approves Iterum's treatment for urinary infection - Reuters
- 6 weeks ago - Iterum Therapeutics to Present Data at IDWeek 2024 - GlobeNewsWire
- 6 weeks ago - Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire